Antithrombotic therapy for the treatment of atrial fibrillation in the elderly

Area of Science:

• Cardiology
• Neurology
• Geriatrics

Background:

• Atrial fibrillation (AF) is a growing concern, particularly in aging populations, significantly increasing ischemic stroke risk.
• Effective antithrombotic therapy is crucial for managing AF-related thromboembolism, with oral vitamin K antagonists (e.g., warfarin) showing high efficacy but posing management challenges and bleeding risks.
• Aspirin offers modest stroke risk reduction but is less effective than warfarin.

Purpose of the Study:

• To review the role of antithrombotic therapy in atrial fibrillation (AF).
• To discuss the benefits and risks of warfarin and aspirin in stroke prevention for AF patients.
• To highlight the need for improved risk stratification, especially for intracranial hemorrhage in elderly AF patients.

Main Methods:

• Literature review on antithrombotic therapies for atrial fibrillation.
• Analysis of stroke and bleeding risk associated with warfarin and aspirin.
• Examination of risk stratification strategies for thromboembolic events and intracranial hemorrhage.

Main Results:

• Warfarin is highly effective in preventing AF-related thromboembolism but requires careful management and increases bleeding risk.
• Aspirin has a more modest effect on stroke risk compared to warfarin.
• Elderly patients on warfarin face higher bleeding rates and intracranial hemorrhage risk, despite generally deriving a net benefit.

Conclusions:

• Optimizing antithrombotic therapy in AF is essential for stroke prevention.
• Current risk stratification methods for stroke and intracranial hemorrhage in AF patients, particularly the elderly, require enhancement.
• Further research is needed to develop more precise tools for identifying patients at high risk of bleeding complications.